Product
Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Evaluate the Immunogenicity and Safety of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Above Who Have Completed Two-dose or Three-dose Inactivated COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2023-01-18